Celyad Oncology SA

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:35:13 2024-07-03 EDT			5-day change	1st Jan Change
0.2755 ^EUR	-4.34%		+0.55%	-29.36%

04-04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Celyad Appoints Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise

January 06, 2016 at 04:43 pm

Celyad announced the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise, effective January 4, 2016.

Latest news about Celyad Oncology SA

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	02-09	MT
Celyad Oncology CEO Resigns	12-05	MT
Celyad Oncology CEO Steps Down for Personal Reasons	12-04	MT
Celyad Oncology SA Announces Executive Change	12-04	CI
Celyad Oncology Sa Announces Executive Change	12-04	CI
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	11-13	CI
Celyad Oncology to Cancel American Depository Receipt Program in October	23-09-26	MT
Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023	23-09-05
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-04	CI
Celyad Oncology Secures EUR10 Million via Private Placement With Historical Investors	23-08-25	MT
Celyad Oncology SA announced that it expects to receive ?9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors	23-08-23	CI
Celyad Oncology SA(OTCUS:CYAD.Y) dropped from NASDAQ Composite Index	23-05-18	CI
Global markets live: Boohoo, KBC, Vodafone, Home Depot, Ford...	23-05-16
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq	23-05-16	MT
Celyad Oncology Receives Delisting Notice From Nasdaq	23-05-15	MT
Forecast-Beating Apple Results Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-05-05	MT
Belgium's Celyad Oncology to Delist ASDs from Nasdaq	23-05-05	MT
Celyad Oncology to Delist From Nasdaq Global Market	23-05-05	MT
Celyad Oncology in Breach of Nasdaq's Listing Rule	23-04-04	MT
Transcript : Celyad Oncology SA, 2022 Earnings Call, Mar 24, 2023	23-03-24
Celyad Oncology SA Appoints Georges Rawadi as its New Chief Executive Officer	23-03-24	CI
Celyad Oncology Names Georges Rawadi as Chief Executive	23-03-24	MT
Celyad Oncology Appoints New CEO	23-03-24	MT
Celyad Oncology SA Auditor Raises 'Going Concern' Doubt	23-03-22	CI

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Sector

Biotechnology & Medical Research

Calendar

2024-09-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELYAD ONCOLOGY SA	-29.36%	12.81M
MODERNA, INC.	+16.59%	44.87B
IQVIA HOLDINGS INC.	-10.62%	37.8B
LONZA GROUP AG	+40.49%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.32B
CELLTRION, INC.	-9.78%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.32B
UNITED THERAPEUTICS CORPORATION	+41.53%	14.07B
MEDPACE HOLDINGS, INC.	+31.49%	12.5B
BIO-TECHNE CORPORATION	-7.40%	11.23B

Other Biotechnology & Medical Research

Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Celyad Appoints Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise

Latest news about Celyad Oncology SA

Chart Celyad Oncology SA

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research